This site is intended for US Healthcare Professionals only

About Mulpleta

Mulpleta is a NEW orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist. It is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.¹

Mulpleta helps increase endogenous platelet production¹

Mulpleta upregulates the production of platelets through its agonistic effect on human TPO receptors.

Activation of the TPO receptor by Mulpleta²

Activation of the TPO receptor by Mulpleta²

Mulpleta helps increase
platelet count for the
majority of patients.

Indication

Mulpleta^® (lusutrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Important Safety Information

Warnings and Precautions

Mulpleta is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Portal vein thrombosis was reported in 1% of Mulpleta-treated patients and 1% of placebo-treated patients.

Consider the potential increased thrombotic risk when administering Mulpleta to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, or Protein C or S deficiency). Monitor platelet counts and for thromboembolic events and institute treatment promptly.

Mulpleta should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Adverse Reactions

The most common adverse reaction (≥3%) with Mulpleta was headache.

To report suspected Adverse Reactions, contact Shionogi at 1-800-849-9707 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information for Mulpleta.

References

Mulpleta (lusutrombopag tablets) [package insert]. Florham Park, NJ: Shionogi Inc.; 2018.
Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607-4616.

About Mulpleta

Mulpleta helps increase endogenous platelet production1

Activation of the TPO receptor by Mulpleta2

Activation of the TPO receptor by Mulpleta2

Indication

Important Safety Information

Warnings and Precautions

Adverse Reactions

Mulpleta helps increase endogenous platelet production¹

Activation of the TPO receptor by Mulpleta²

Activation of the TPO receptor by Mulpleta²